Get Relief from Complicated, Highly Variable ADCC Assays with the ADCC Reporter Bioassays

Copyright Promega.
Copyright Promega.
Traditional mechanism-of-action ADCC assays are fraught with difficulty from isolating specific populations of cells from blood to maintaining well-controlled assay conditions. This can lead to highly variable results that are difficult to replicate. The ADCC Reporter Bioassays eliminate much of this variability by providing frozen, thaw-and-use effector cells—cells as critical, quality-controlled reagents, giving you confidence in your results. The video below illustrates the ADCC Reporter Bioassay Principle.

For more information, links to the protocols are provided below.

ADCC Reporter Bioassay, Core Kit

ADCC Reporter Bioassay, Complete Kit (WIL2-S)

ADCC Reporter Bioassay, Complete Kit (Raji)

ADCC Bioassay Effector Cells, Cell Propagation Model



Top 10 Innovator—Two Years Running

The ADCC Reporter Bioassays were named a Top 10 innovation by The Scientist Magazine.
The ADCC Reporter Bioassay systems were named a Top 10 innovation by The Scientist Magazine.
For the second year running a Promega technology has made The Scientist Magazine’s list of Top 10 Innovations. Last year it was the NanoLuc® luciferase technology; this year it is the ADCC Reporter Bioassay.

Antibody-dependent cell-mediated cytotoxicity (ADCC) is the main mechanism of action (MOA) of antibodies through which virus-infected or other diseased cells are targeted for destruction by components of the cell-mediated immune system. ADCC assays are often used to assess the effectiveness of monoclonal antibody therapies during the manufacture and development of biologic drugs. The bioluminescent ADCC Reporter Bioassays use an alternative readout at an earlier point in ADCC MOA pathway for the quantification of Fc effector function of antibody-based molecules: the activation of gene transcription through the NFAT (nuclear factor of activated T-cells) pathway in the effector cell.

The bioassay uses engineered Jurkat cells stably expressing the FcγRIIIa receptor, V158 (high affinity) variant, and an NFAT response element driving expression of firefly luciferase. The assay is ADCC MOA-based and features frozen, thaw-and-use effector cells and optimized reagents and protocol to perform a reporter-based ADCC bioassay in a single day. The ADCC Reporter Bioassay correlates with classic cytotoxic ADCC assays and is a suitable replacement for these cumbersome and highly variable assays.

The novel bioassay is linear, accurate, precise and stability indicating. Moreover, the bioassay shows good linear correlation between levels of glycosylation or fucosylation and ADCC activity. All of these features indicate the assay is suitable for use across biologic drug development programs.

Resources for the ADCC Reporter Bioassays: